Company profile: AN2 Therapeutics
1.1 - Company Overview
Company description
- Provider of boron chemistry–based drug discovery and clinical development for infectious diseases, including epetraborole, an oral therapy in development for chronic non-tuberculous mycobacterial lung disease targeting Mycobacterium avium complex, and conducting clinical trials to obtain regulatory approval for new medications for infectious diseases.
Products and services
- Boron-based Drug Discovery Platform: A boron-based research and development approach that architects novel compounds for treating infectious diseases by exploiting boron chemistry to engineer anti-infective candidates
- Clinical Trials: Conducts regulatory-focused clinical studies to gain approval for new medications aimed at treating infectious diseases through rigorous, protocol-driven investigation
- Epetraborole: An oral treatment being developed to treat chronic non-tuberculous mycobacterial lung disease by specifically targeting Mycobacterium avium complex (MAC) pathogens for improved anti-infective efficacy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AN2 Therapeutics
Spring Bank Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule nucleic acid hybrid-based therapeutics and immuno-oncology candidates, including FS118, a LAG-3/PD-L1 mAb2 bispecific antibody in Phase 2 for head and neck cancer, NSCLC and DLBCL; FS120, an OX40/CD137 dual agonist mAb2 in Phase 1; FS222, a CD137/PD-L1 mAb2 in Phase 1 for PD-L1-low tumors; and SB 11285, an IV second-generation STING agonist in Phase 1, alone and with atezolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spring Bank Pharmaceuticals company profile →
IGeneX
HQ: United States
Website
- Description: Provider of diagnostic solutions for tick-borne diseases, offering culture enhanced PCR, PCR, serology, ImmunoBlots, and FISH tests for Lyme disease, Bartonella, Babesia, and tick-borne relapsing fever, plus tick testing for pathogen detection and training services; engaged in research and development of tests that accurately detect these pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IGeneX company profile →
Anadys Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for chronic hepatitis C, developing ANA598, a direct-acting antiviral (DAA), and resuming clinical development of ANA773.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anadys Pharmaceuticals company profile →
Noscendo
HQ: Germany
Website
- Description: Provider of digital diagnostics for identification and assessment of bloodstream-associated pathogens and other infections. Offers DISQVER, a next-generation sequencing and bioinformatics platform that identifies over 16,000 microbes, including 1,500 pathogens, from a single blood sample within 24 hours.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noscendo company profile →
Mpex Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development of new therapies to combat antibiotic resistance, with a particular focus on gram-negative organisms. The company's internal pipeline combines proprietary formulations, PK/PD strategies and novel potentiating agents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mpex Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AN2 Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AN2 Therapeutics
2.2 - Growth funds investing in similar companies to AN2 Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AN2 Therapeutics
4.2 - Public trading comparable groups for AN2 Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →